JP2016034975A - 抗体および抗体含有組成物 - Google Patents
抗体および抗体含有組成物 Download PDFInfo
- Publication number
- JP2016034975A JP2016034975A JP2015227426A JP2015227426A JP2016034975A JP 2016034975 A JP2016034975 A JP 2016034975A JP 2015227426 A JP2015227426 A JP 2015227426A JP 2015227426 A JP2015227426 A JP 2015227426A JP 2016034975 A JP2016034975 A JP 2016034975A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- bacteria
- virus
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title abstract description 15
- 239000000427 antigen Substances 0.000 abstract description 44
- 102000036639 antigens Human genes 0.000 abstract description 44
- 108091007433 antigens Proteins 0.000 abstract description 44
- 241000894006 Bacteria Species 0.000 abstract description 25
- 241000700605 Viruses Species 0.000 abstract description 22
- 230000001580 bacterial effect Effects 0.000 abstract description 19
- 239000000126 substance Substances 0.000 abstract description 14
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 8
- 208000015181 infectious disease Diseases 0.000 abstract description 7
- 108010052285 Membrane Proteins Proteins 0.000 abstract description 5
- 102000018697 Membrane Proteins Human genes 0.000 abstract description 5
- 241000271566 Aves Species 0.000 abstract description 4
- 230000035755 proliferation Effects 0.000 abstract description 3
- 230000001404 mediated effect Effects 0.000 abstract 1
- 241000272534 Struthio camelus Species 0.000 description 30
- 230000003053 immunization Effects 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 25
- 210000002969 egg yolk Anatomy 0.000 description 21
- 238000002649 immunization Methods 0.000 description 21
- 102000002322 Egg Proteins Human genes 0.000 description 20
- 108010000912 Egg Proteins Proteins 0.000 description 20
- 235000013345 egg yolk Nutrition 0.000 description 20
- 241000725303 Human immunodeficiency virus Species 0.000 description 19
- 239000000243 solution Substances 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 238000002965 ELISA Methods 0.000 description 14
- 239000003656 tris buffered saline Substances 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 235000013601 eggs Nutrition 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 241000186427 Cutibacterium acnes Species 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 208000020154 Acnes Diseases 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 239000000147 enterotoxin Substances 0.000 description 5
- 231100000655 enterotoxin Toxicity 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- 206010003645 Atopy Diseases 0.000 description 4
- 101710146739 Enterotoxin Proteins 0.000 description 4
- 241001631646 Papillomaviridae Species 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- 241000701447 unidentified baculovirus Species 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 108010065152 Coagulase Proteins 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 101000794214 Staphylococcus aureus Toxic shock syndrome toxin-1 Proteins 0.000 description 3
- 241000271567 Struthioniformes Species 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 229920001342 Bakelite® Polymers 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 238000011091 antibody purification Methods 0.000 description 2
- 239000004637 bakelite Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000009422 growth inhibiting effect Effects 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940055019 propionibacterium acne Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 231100000617 superantigen Toxicity 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 244000036975 Ambrosia artemisiifolia Species 0.000 description 1
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000218691 Cupressaceae Species 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- 241000201788 Staphylococcus aureus subsp. aureus Species 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000003484 annual ragweed Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000006263 bur ragweed Nutrition 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000003488 common ragweed Nutrition 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- -1 nose drops Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 235000009736 ragweed Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14041—Use of virus, viral particle or viral elements as a vector
- C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本発明はまた、以下の項目を提供する。
(項目1) 菌体の破砕液を抗原とする抗体。
(項目2) 上記抗体は上記菌体の破砕液を抗原として免疫した鳥類の卵から得られたIgYである項目1に記載の抗体。
(項目3) 上記鳥類はダチョウである項目2に記載された抗体。
(項目4) 上記菌体は、Stapylococcus aureusである請求項1乃至3のいずれかの項目に記載された抗体。
(項目5) 上記菌体は、Propionibacterium acnesである項目1乃至3のいずれかに記載された抗体。
(項目6) ウイルスの表面タンパク質を抗原とする抗体。
(項目7) 上記抗体は上記タンパク質を抗原として免疫した鳥類の卵から得られたIgYである項目6に記載の抗体。
(項目8) 上記鳥類はダチョウである項目7に記載された抗体。
(項目9) 上記タンパク質は、HIVgp120を含む項目6乃至8のいずれかの項目に記載された抗体。
(項目10) 上記タンパク質は、HPVのtype6、11、16、18のいずれかを含む項目6乃至8のいずれかの項目に記載された抗体。
(項目11) 項目1乃至10のいずれかの抗体と基剤を含む抗体含有組成物。
(項目12) 上記基剤はワセリンである項目11記載の抗体含有組成物。
本発明の効果を示す実施例として対象とした細菌は、黄色ブドウ球菌 Staphylococcus aureus (NBRC102135)(以下 S. aureus)、アクネ菌 Propionibacterium acnes (NBRC107605) (以下 P. acnes)の2種類である。
初回免疫は、フロイントの完全アジュバントにタンパク質量として100μgの上記それぞれのホモジネートを混和し、メスのダチョウの腰部の筋肉内に接種した。その後、追加免疫として、初回免疫後上記2種類のホモジネートは、ともに隔週毎に3回追加免疫した。なお、この追加免疫の場合も、フロイントの不完全アジュバントに100μgのバクテリアホモジネート液を混和し、すでに免疫を行っているメスのダチョウの腰部の筋肉内に接種した。
追加免疫2週後以降に産卵されるダチョウ卵より抗体を精製した。抗体の精製法を以下に示す。卵黄からの抗体(IgY)の精製は以下のように行った。
以下のELISAにより、得られた抗体の抗原反応性を測定した。
2μg/mLのバクテリア菌体(S.aureus、P.acnes)、S.aureusのenterotoxins(エンテロトキシン)、S.aureusのTSST−1,コアグラーゼ、プロテアーゼをそれぞれELISA用96穴マイクロプレートの各wellに100μl入れ、室温で2時間放置した。その後、PBSで3回洗浄したのち、市販のブロッキング溶液(ブロックエース:大日本住友製薬)を各wellに100μl入れ2時間放置した。その後、PBSで3回洗浄したのち、免疫前および免疫後のダチョウIgY抗体の段階希釈液(2mg/mLを原液として100倍、200倍〜と2倍段階希釈)を各wellに50μl入れ室温で1時間放置した。
培養前のバクテリア液(S.aureus、P.acnes)に1mg/mLとなるようにダチョウ卵黄抗体を混和し、それぞれ寒天培地(半径10cmのシャーレにバクテリア液0.1mlを培養)にて18時間培養した。バクテリアのコロニーをカウントしPFU(プラークフォーミングユニット)を算出した。図1にその結果を示す。図1(a)はS.aureusの場合で、図1(b)は、P.acnesの場合である。横軸は免疫前抗体の場合と、免疫後抗体の場合を示す。縦軸はPFU(×105/100μL)である。どちらの抗体も抗原であるバクテリアの増殖を抑制していた。
培養前のS.aureus液に1mg/mLとなるようにダチョウ卵黄抗体(S.aureusを免疫して得た抗体)を混和し、寒天培地(半径10cmのシャーレにバクテリア液0.1mlを培養)にて18時間培養した。結果は図2の写真に示す。免疫前抗体(図2(a)左写真)および免疫後(図2(b)右写真)の抗体を混和した結果である。免疫抗体の混和により、バクテリアのコロニー(白点)数が明らかに減少していることが分かる。つまり抗体によりバクテリアの増殖が抑制されていた。
S.aureus、P.acnesの免疫により作製したダチョウ卵黄抗体をワセリン(基剤)に混和(抗体濃度が50μg/mLになるように調整)し、アトピーおよびニキビ罹患人に軟膏として患部に塗布した。一日2回の使用を毎日連続して行い、1週間目の患部の状態を観察した。比較対象には基剤のみを使用した。結果を表3に示す。ここで、「S.aureus抗体」は、S.aureus菌体のホモジネート液を抗原として得た抗体を示し、「P.acnes抗体」は、P.acnes菌体のホモジネート液を抗原として得た抗体を示す。「混合抗体」は、「S.aureus抗体」と「P.acnes抗体」を50対50で混合したものを基剤に混和(全抗体濃度が50μg/mLになるように調整)したものである。
HIVそのものではなく、HIVの表面タンパク質を、遺伝子工学的にバキュロウイルスにより作製されたリコンビナント蛋白質HIVgp120とHIV160を抗原として用いた。HIVgp120とHIVgp160はHIVがヒト細胞に感染するのに必要な蛋白質であり、これらに対する抗体を作製すればHIVの感染を抑制できると考えられる。1匹のダチョウへの免疫はHIVgp120を50μg、HIVgp160を50μgを混合したものを用いた。
子宮頸ガンを誘発するHPV type6、11、16、18を用いた(計4種の抗原)。HPVそのものではなく、遺伝子工学的にバキュロウイルスにより作製されたウイルスのL1タンパク質(リコンビナントタンパク質)を抗原として用いた。1匹のダチョウへの免疫は上記4種類の抗原(各40μg)を混合したものを用いた。
HIVとHPVはそれぞれ別のダチョウに免疫した。初回免疫は、フロイントの完全アジュバントにタンパク質量として100μgの上記ウイルス抗原を混和し、メスのダチョウの腰部の筋肉内に接種した。また、追加免疫として、初回免疫後、上記2パターンともに隔週毎に3回追加免疫した。フロイントの不完全アジュバントに100μgの抗原を混和し、メスのダチョウの腰部の筋肉内に接種した。
追加免疫2週後以降に産卵されるダチョウ卵より抗体を精製した。抗体の精製法を以下に示す。
以下のELISAにより、得られた抗体の抗原反応性を測定した。2μg/mLのHIVgp120、HIVgp160、HPV type6、11、16、18をそれぞれELISA用96穴マイクロプレートの各wellに100μl入れ、室温で2時間放置した。
上記ダチョウ卵黄抗体(HIV、HPV)をローション(性交時に直接使用、コンドームの表面にも使用)に混和した。ダチョウ卵黄抗体1mgを10mLのローション液(成分:水、グリセリン、エタノール、ポリアクリル酸Na,ヒドロキシエチルセルロース、フェノキシエタノール、EDTA−2Na,パラベン、ポリソルベート80,脂肪酸ソルビタン)と混和した。この混和液中の抗体活性(HIV、HPVの各抗原)を上記と同様のELISAにより測定した。
表4にHIVgp120とHIVgp160の場合のELISAの結果を示す。表中の数値は、免疫前抗体の吸光度値の2倍以上となる最高希釈倍率である。HIV感染に重要とされるHIVgp120とHIVgp160に対して高い力価の抗体が産生されることが判明した。また、ローションに混和しても抗体活性が全く失われないことが判明した。
Claims (1)
- 本明細書に記載の発明。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015227426A JP6441782B2 (ja) | 2011-08-19 | 2015-11-20 | 抗体および抗体含有組成物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011179378 | 2011-08-19 | ||
JP2011179378 | 2011-08-19 | ||
JP2015227426A JP6441782B2 (ja) | 2011-08-19 | 2015-11-20 | 抗体および抗体含有組成物 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013529859A Division JP5845265B2 (ja) | 2011-08-19 | 2012-08-09 | 抗体および抗体含有組成物 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018174078A Division JP6830462B2 (ja) | 2011-08-19 | 2018-09-18 | 抗体および抗体含有組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016034975A true JP2016034975A (ja) | 2016-03-17 |
JP6441782B2 JP6441782B2 (ja) | 2018-12-19 |
Family
ID=47746128
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013529859A Active JP5845265B2 (ja) | 2011-08-19 | 2012-08-09 | 抗体および抗体含有組成物 |
JP2015227426A Active JP6441782B2 (ja) | 2011-08-19 | 2015-11-20 | 抗体および抗体含有組成物 |
JP2018174078A Active JP6830462B2 (ja) | 2011-08-19 | 2018-09-18 | 抗体および抗体含有組成物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013529859A Active JP5845265B2 (ja) | 2011-08-19 | 2012-08-09 | 抗体および抗体含有組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018174078A Active JP6830462B2 (ja) | 2011-08-19 | 2018-09-18 | 抗体および抗体含有組成物 |
Country Status (9)
Country | Link |
---|---|
US (5) | US20140234337A1 (ja) |
EP (2) | EP3406716B1 (ja) |
JP (3) | JP5845265B2 (ja) |
KR (2) | KR101911229B1 (ja) |
CN (1) | CN103890173B (ja) |
AU (1) | AU2012298125B2 (ja) |
MY (1) | MY166794A (ja) |
TW (1) | TWI548420B (ja) |
WO (1) | WO2013027356A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106279349A (zh) * | 2016-08-31 | 2017-01-04 | 广东工业大学 | 用于制备卵黄抗体的皮肤癣菌细胞浆蛋白抗原的提取方法及其卵黄抗体的制备方法 |
CN106397586A (zh) * | 2016-08-31 | 2017-02-15 | 广东工业大学 | 一种抗皮肤癣菌的特异性卵黄抗体及其制备方法和应用 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101911229B1 (ko) | 2011-08-19 | 2018-10-24 | 임모탈 스피릿 리미티드 | 항체 및 항체 함유 조성물 |
JP2017006008A (ja) * | 2015-06-17 | 2017-01-12 | オーストリッチファーマ株式会社 | Mers用抗体および抗血清 |
WO2017217744A1 (ko) * | 2016-06-13 | 2017-12-21 | (주)이앤에스헬스케어 | 파지 디스플레이 기술을 이용한 여드름 균에 특이적으로 결합하는 인간 항체 및 이의 용도 |
US11141369B2 (en) | 2016-06-13 | 2021-10-12 | E&S Healthcare Co., Ltd. | Human antibody specifically binding to acne bacteria using phage display technique, and use thereof |
WO2019087372A1 (ja) * | 2017-11-02 | 2019-05-09 | オーストリッチファーマ株式会社 | 細菌感染症用ダチョウ抗体 |
CN108042387A (zh) * | 2017-12-11 | 2018-05-18 | 陕西瑞凯生物科技有限公司 | 一种生物蛋白抑菌漱口水及其制备方法 |
JP6586450B2 (ja) * | 2017-12-20 | 2019-10-02 | オーストリッチファーマ株式会社 | アレルゲン抗体およびそれを有する組成物 |
CN108714214A (zh) * | 2018-05-30 | 2018-10-30 | 芬多精(厦门)生物技术有限公司 | 一种纯天然妇科桧洗剂及其制备方法 |
JP7226766B2 (ja) * | 2018-10-17 | 2023-02-21 | オーストリッチファーマ株式会社 | 毛髪の改善のための抗体 |
CN110680917A (zh) * | 2019-09-30 | 2020-01-14 | 南京道大药业有限公司 | 一种抗痤疮丙酸杆菌、葡萄球菌复合IgY抗原制备方法及其应用 |
US11319382B1 (en) | 2021-06-28 | 2022-05-03 | King Abdulaziz University | Methods for producing and using IgY antibodies targeting the middle east respiratory syndrome coronavirus spike protein to treat or prevent MERS-CoV infection |
CN113278064B (zh) * | 2021-07-20 | 2021-11-02 | 山东信得科技股份有限公司 | 一种用于胚毒类抗原净化处理的方法及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005537028A (ja) * | 2002-06-26 | 2005-12-08 | ザ ペン ステート リサーチ ファウンデーション | ヒト乳頭腫ウイルス感染症を治療する方法及び材料 |
JP2007084495A (ja) * | 2005-09-22 | 2007-04-05 | Daikin Ind Ltd | ウイルス感染細胞処理方法 |
JP2009023985A (ja) * | 2007-01-11 | 2009-02-05 | Osaka Prefecture Univ | インフルエンザウイルスに対する抗体の産生方法 |
JP2010013361A (ja) * | 2008-07-01 | 2010-01-21 | Ostrich Pharma Kk | ノロウイルスに対する抗体及び抗体の作成方法 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02121910A (ja) * | 1988-10-28 | 1990-05-09 | Kanebo Ltd | にきび用化粧料 |
IL102092A (en) | 1991-06-11 | 1996-11-14 | Microgenesys Inc | Use of recombinant VIH protein wrapped in VIH abduction drug and a pharmaceutical preparation containing the accumulated protein |
JPH1084969A (ja) | 1996-09-19 | 1998-04-07 | Chemo Sero Therapeut Res Inst | ヘモフィルス・パラガリナルム由来新規ポリペプチド及びその製法 |
AU729502B2 (en) | 1996-10-02 | 2001-02-01 | Ovimmune, Inc. | Oral administration of chicken yolk antibodies to treat disease |
CN1107147C (zh) | 1998-11-09 | 2003-04-30 | 柳州欧维姆建筑机械有限公司 | 一种斜拉桥钢绞线拉索的挂索方法 |
JP2003503015A (ja) * | 1999-05-03 | 2003-01-28 | メダレツクス・インコーポレーテツド | スタフィロコッカス・アウレウスに対するヒト抗体 |
JP3504633B2 (ja) * | 1999-10-29 | 2004-03-08 | わかもと製薬株式会社 | ヘリコバクター・ピロリへの感染を判定する検査方法及び検査試薬 |
CN1195869C (zh) | 1999-10-29 | 2005-04-06 | 若素制药株式会社 | 单克隆抗体、杂交瘤、免疫测定法和诊断试剂盒 |
US6162441A (en) * | 1999-12-15 | 2000-12-19 | Republic Of Korea (Management: Rural Development Administration) | Method for the production of anti-escherichia. coli O157 : H7 antibody |
US7005503B2 (en) * | 2002-02-08 | 2006-02-28 | Genetastix Corporation | Human monoclonal antibody against coreceptors for human immunodeficiency virus |
KR20020044851A (ko) * | 2000-12-07 | 2002-06-19 | 최승철 | 여드름 예방 및 치료용 스핑고리피드 조성물 |
US7300916B2 (en) | 2001-02-27 | 2007-11-27 | Yoshiko Yasuda | Preventives/remedies for thickened scar, keloid or chronic arthritic diseases |
JP4081281B2 (ja) * | 2001-02-27 | 2008-04-23 | 佳子 安田 | 肥厚性瘢痕、ケロイドまたは慢性関節炎症性疾患予防・治療剤 |
KR100446856B1 (ko) * | 2001-04-14 | 2004-09-04 | 주식회사 콧데 | 항비듬균 면역항체와 그 용도 |
GB0110431D0 (en) * | 2001-04-27 | 2001-06-20 | Glaxosmithkline Biolog Sa | Novel compounds |
CN1362418A (zh) * | 2001-12-21 | 2002-08-07 | 重庆和润实业(集团)有限公司 | 抗霍乱弧菌、其毒素鸡卵黄抗体及其制备与应用 |
CN1207057C (zh) * | 2002-06-11 | 2005-06-22 | 雅臣药业集团(远东)有限公司 | 抗咽喉炎特异性复合IgY及其制剂 |
CN1454901A (zh) * | 2003-06-10 | 2003-11-12 | 雅臣药业集团(远东)有限公司 | 抗妇科感染特异性IgY及其组合制剂 |
CN1569896A (zh) * | 2003-07-18 | 2005-01-26 | 广州新崴生物医药科技有限公司 | 抗皮肤感染特异性复合卵黄抗体igy的制备及其在皮肤感染治疗上的应用 |
CN1283663C (zh) * | 2005-01-12 | 2006-11-08 | 江西3L医用制品集团有限公司 | 抗溶血性链球菌、葡萄球菌及白色念珠菌IgY抗体及制备方法 |
AU2006285850A1 (en) | 2005-08-29 | 2007-03-08 | Japan Science And Technology Agency | Antibody produced using ostrich and method for production thereof |
TWI307631B (en) * | 2006-01-03 | 2009-03-21 | Livestock Res Inst Council Of Agriculture Executive Yuan | Composition for treating and/or preventing enterovirus |
JP2008169142A (ja) * | 2007-01-11 | 2008-07-24 | Osaka Prefecture Univ | 食中毒菌に対する抗体の産生方法 |
KR100925479B1 (ko) * | 2007-09-19 | 2009-11-06 | 한국전자통신연구원 | 음성 인식 방법 및 장치 |
JP2009233557A (ja) | 2008-03-26 | 2009-10-15 | Fujifilm Corp | 有害物質除去材及びそれを用いた空気清浄化装置 |
KR101085540B1 (ko) * | 2009-04-08 | 2011-11-24 | (주)애드바이오텍 | 여드름균에 대한 항체를 지닌 난황을 함유하는 여드름 개선용 화장료 조성물 |
JP5439127B2 (ja) * | 2009-11-13 | 2014-03-12 | 株式会社さいわいメディカル | 乾癬又はアトピー性皮膚炎治療剤 |
KR101911229B1 (ko) * | 2011-08-19 | 2018-10-24 | 임모탈 스피릿 리미티드 | 항체 및 항체 함유 조성물 |
-
2012
- 2012-08-09 KR KR1020167024373A patent/KR101911229B1/ko active IP Right Grant
- 2012-08-09 WO PCT/JP2012/005056 patent/WO2013027356A1/ja active Application Filing
- 2012-08-09 CN CN201280040447.0A patent/CN103890173B/zh active Active
- 2012-08-09 MY MYPI2014700358A patent/MY166794A/en unknown
- 2012-08-09 JP JP2013529859A patent/JP5845265B2/ja active Active
- 2012-08-09 EP EP18164280.2A patent/EP3406716B1/en active Active
- 2012-08-09 US US14/239,776 patent/US20140234337A1/en not_active Abandoned
- 2012-08-09 AU AU2012298125A patent/AU2012298125B2/en active Active
- 2012-08-09 EP EP12826119.5A patent/EP2746394A4/en not_active Ceased
- 2012-08-09 KR KR1020147007157A patent/KR101655964B1/ko active IP Right Grant
- 2012-08-17 TW TW101129893A patent/TWI548420B/zh active
-
2015
- 2015-11-20 JP JP2015227426A patent/JP6441782B2/ja active Active
-
2016
- 2016-08-05 US US15/230,188 patent/US9828419B2/en active Active
-
2017
- 2017-11-09 US US15/808,807 patent/US10106599B2/en active Active
-
2018
- 2018-09-17 US US16/133,493 patent/US10428138B2/en active Active
- 2018-09-18 JP JP2018174078A patent/JP6830462B2/ja active Active
-
2019
- 2019-08-19 US US16/544,784 patent/US11041016B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005537028A (ja) * | 2002-06-26 | 2005-12-08 | ザ ペン ステート リサーチ ファウンデーション | ヒト乳頭腫ウイルス感染症を治療する方法及び材料 |
JP2007084495A (ja) * | 2005-09-22 | 2007-04-05 | Daikin Ind Ltd | ウイルス感染細胞処理方法 |
JP2009023985A (ja) * | 2007-01-11 | 2009-02-05 | Osaka Prefecture Univ | インフルエンザウイルスに対する抗体の産生方法 |
JP2010013361A (ja) * | 2008-07-01 | 2010-01-21 | Ostrich Pharma Kk | ノロウイルスに対する抗体及び抗体の作成方法 |
Non-Patent Citations (2)
Title |
---|
VACCINE, vol. 24, JPN6017024433, 2006, pages 5571 - 5583, ISSN: 0003796626 * |
ウイルス, vol. 58, no. 2, JPN6017024434, 2008, pages 155 - 164, ISSN: 0003796627 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106279349A (zh) * | 2016-08-31 | 2017-01-04 | 广东工业大学 | 用于制备卵黄抗体的皮肤癣菌细胞浆蛋白抗原的提取方法及其卵黄抗体的制备方法 |
CN106397586A (zh) * | 2016-08-31 | 2017-02-15 | 广东工业大学 | 一种抗皮肤癣菌的特异性卵黄抗体及其制备方法和应用 |
CN106397586B (zh) * | 2016-08-31 | 2019-12-06 | 广东工业大学 | 一种抗皮肤癣菌的特异性卵黄抗体及其制备方法和应用 |
CN106279349B (zh) * | 2016-08-31 | 2019-12-10 | 广东工业大学 | 用于制备卵黄抗体的皮肤癣菌细胞浆蛋白抗原的提取方法及其卵黄抗体的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
EP2746394A1 (en) | 2014-06-25 |
JP6441782B2 (ja) | 2018-12-19 |
KR20160108593A (ko) | 2016-09-19 |
KR101655964B1 (ko) | 2016-09-08 |
US10428138B2 (en) | 2019-10-01 |
US20190375827A1 (en) | 2019-12-12 |
MY166794A (en) | 2018-07-23 |
JP5845265B2 (ja) | 2016-01-20 |
JP6830462B2 (ja) | 2021-02-17 |
US20140234337A1 (en) | 2014-08-21 |
CN103890173A (zh) | 2014-06-25 |
US20190016788A1 (en) | 2019-01-17 |
EP3406716A1 (en) | 2018-11-28 |
CN103890173B (zh) | 2016-02-03 |
TWI548420B (zh) | 2016-09-11 |
EP3406716B1 (en) | 2023-10-04 |
JPWO2013027356A1 (ja) | 2015-03-05 |
US10106599B2 (en) | 2018-10-23 |
US20180066042A1 (en) | 2018-03-08 |
EP2746394A4 (en) | 2015-07-15 |
TW201313248A (zh) | 2013-04-01 |
KR101911229B1 (ko) | 2018-10-24 |
WO2013027356A1 (ja) | 2013-02-28 |
KR20140047161A (ko) | 2014-04-21 |
AU2012298125A1 (en) | 2014-03-13 |
AU2012298125B2 (en) | 2015-09-24 |
JP2019006817A (ja) | 2019-01-17 |
US11041016B2 (en) | 2021-06-22 |
US9828419B2 (en) | 2017-11-28 |
US20160340416A1 (en) | 2016-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6441782B2 (ja) | 抗体および抗体含有組成物 | |
JP6420417B2 (ja) | バイオフィルムを除去するための組成物および方法 | |
RU2010111758A (ru) | Иммуногенные композиции и способы | |
WO2023024609A1 (zh) | 一种新型冠状病毒疫苗的佐剂及其应用和新型冠状病毒二价重组疫苗 | |
WO2020192080A1 (zh) | 一种人7型腺病毒抗体及其应用 | |
CA2257826A1 (en) | Helicobacter pylori adhesin binding group antigen | |
JP2013147471A (ja) | ダチョウ抗体水溶液 | |
US20020086022A1 (en) | Neutralizing antibody and immunomodulatory enhancing compositions | |
WO2014146603A1 (zh) | 败血性巴氏杆菌毒素重组蛋白及其应用 | |
WO2021003867A1 (zh) | 一种单克隆抗体10g12及其应用 | |
Xun et al. | Protective effects of sucralfate on anti–H. pylori VacA IgY in vivo and in vitro | |
JP2015509083A5 (ja) | ||
Rodriguez et al. | The Effect of the Anti-Covid-19 Vaccine Abdala Dose Level and Dosing Interval in Rats and Cynomolgus Monkeys | |
WO2018178593A1 (fr) | Composition d'immunoglobulines utiles pour traiter des infections virales | |
WO2002026259A1 (fr) | Medicament pour le traitement du sida et son procede de preparation | |
JPH02101023A (ja) | オーエスキー病のサブユニットワクチン、及び製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151218 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161007 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170105 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170303 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170407 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170630 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170926 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171229 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20171229 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180516 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180918 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20180927 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181030 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181122 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6441782 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |